Navigation Links
Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
Date:4/16/2008

>Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein relating to Phase 1/2 clinical data of MDX-060 in lymphoma may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... LEXINGTON, Ky. (PRWEB) March 03, 2015 ... aligning their schedules for one event: the Alltech REBELation ... USA, from May 17-20. Now in its 31st year, ... people from 70 countries, and the opportunity to join ... week, March 7 at 11:59 p.m. EST, at which ...
(Date:3/3/2015)... 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life sciences ... products for advanced microarray diagnostics, today announced it ... its Management team. In his capacity as CFO ... from a development stage to a commercially successful ... Company,s capital market strategy and to secure funding ...
(Date:3/3/2015)... FALLS, N.J. , March 3, 2015  Regenicin, ... biotechnology company specializing in the development of and commercialization ... damaged tissues and organs, announced today that it has ... Agreement with Amarantus Bioscience Holdings, Inc. (OTC Bulletin Board: ... under the Agreement, Amarantus made the final payments due ...
(Date:3/3/2015)... 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... journal, Expert Opinion on Biological Therapy , Dr. ... Zhenggang Zhang , at the Henry Ford Hospital in ... beta 4 (TB4) has the capacity to promote CNS ... more post-injury, leading to neurological recovery in each case.  ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... ... announced that its Vice President of eLearning and Informatics earned the ... Society for Training and Development (ASTD) Certification Institute. Michelle Flewell ... training experience and is responsible for the development of the company,s ...
... ... Human Anthrax Vaccine Program must be stopped. Scott Miller and Company ... one-hour television documentary "Fatal Immunity: The Human Anthrax Vaccine Story" to inform ... science turned into for-profit human anthrax vaccines with no accountability to its ...
... Nov. 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... Credit Suisse 18th Annual Healthcare Conference on Wednesday, November ... Time). Interested parties may access a live webcast ... http://www.onyx-pharm.com/view.cfm/32/Event-Calendar , It is recommended that listeners ...
Cached Biology Technology:BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 2BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 3BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 4Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 2Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 3Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 4Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 5Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 6Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 7
(Date:1/22/2015)... 2015  Today, FreeWavz ( www.FreeWavz.com ), the developer ... on Fundable, https://www.fundable.com/freewavz . FreeWavz will be ... to meet customer demand. Logo - ... Invented by Dr. ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of ... and other mental capabilities in adults with mild cognitive ... study led by researchers at Wake Forest Baptist Medical ... diagnosed with amnesic mild cognitive impairment (MCI) or mild ...
(Date:1/22/2015)... Report Issued by Small Cap IR. In 2011, Nilson Report,s ... at merchants on the leading payment cards rose to $135.3 ... and prepaid cards reached 6.54 billion.  Eight million credit card ... in 2012, and credit and debit card fraud resulted in ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... For 25 years, researchers have tried and failed to develop ... of engineered "super antibodies" to fend off the virus ... have proved impossible to produce in people. Now, in research ... scientists at The Rockefeller University have laid out a new ...
... of iron homeostasis is a common feature of prion ... new study by Dr. Neena Singh and colleagues at ... from Creighton University. These findings, published March 13 in ... insight into the mechanism of neurotoxicity in prion disorders, ...
... at Kansas State,University, with collaboration from Epitopix LLC, ... E. coli O157 in beef cattle. ... on the post-harvest food safety,aspect, whether it,s ... of,K-State,s College of Veterinary Medicine. Thomson is the ...
Cached Biology News:A natural approach for HIV vaccine 2A natural approach for HIV vaccine 3Iron is involved in prion disease-associated neuronal demise 2K-State researchers help Epitopix license the United States' first E. coli O157 vaccine for cattle 2
GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
GENOMIPHI HY KIT 1000 RXN, 1 EA. Category: Genomics DNA Amplification....
Human Xg Affinity Purified Polyclonal Ab Keywords: Xg glycoprotein, hereditary hemorrhagic telangiectasia Protein Family: ...
nuclear RNA export factor 1, mRNA...
Biology Products: